Fulcrum Therapeutics Inc. (FULC) NASDAQ

$7.35 (0.46) (-5.89%)

Market Cap: $464.51M

As of 04/15/24 03:59 PM EDT. Market closed.

(FULC)

Fulcrum Therapeutics Inc. (FULC)
NASDAQ

$7.35
(0.46) (-5.89%)

Market Cap: $464.51M

As of 04/15/24 03:59 PM EDT. Market closed.

Add to Portfolio

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their ... read more

what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Full Time Employees
111
Address
.
PRICE CHART FOR FULCRUM THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$7.57
Previous Close
$7.81
Days Range
$7.49 - $7.81
52 week range
$2.42 - $13.70
Volume
438,022
Avg. Volume (30 days)
583,918
Market Cap
$464.51M
Dividend Yield
-
P/E
(4.77)
Shares Outstanding
61,935,171
Open
$7.57
Previous Close
$7.81
Days Range
$7.49 - $7.81
52 week range
$2.42 - $13.70
Volume
438,022
Avg. Volume (30 days)
583,918
Market Cap
$464.51M
Dividend Yield
-
P/E
(4.77)
Shares Outstanding
61,935,171
FINANCIAL STATEMENTS FOR FULCRUM THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR FULCRUM THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Tourangeau GregVice President, FinanceMar 08, 2024 Sale$11.724,88457,21911,807Mar 08, 2024, 06:05 PM
Tourangeau GregPrincipal Accounting OfficerMay 10, 2023 Sale$3.3121069515,992May 11, 2023, 04:12 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJan 20, 2023 Buy$13.001,923,07624,999,98811,609,704Jan 24, 2023, 04:30 PM
Gould Robert JInterim President & CEOJan 13, 2023 Sale$15.006,766101,490499,864Jan 13, 2023, 06:33 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJan 04, 2023 Buy$7.28180,7031,314,8069,686,628Jan 06, 2023, 04:39 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 27, 2022 Buy$5.994,08924,5109,505,925Dec 29, 2022, 05:00 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 19, 2022 Buy$5.9098,787582,8149,501,836Dec 21, 2022, 04:30 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 16, 2022 Buy$5.421,341,4207,269,8269,403,049Dec 16, 2022, 04:41 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 15, 2022 Buy$5.49237,0291,302,4748,061,629Dec 16, 2022, 04:41 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 14, 2022 Buy$5.46824,6004,501,5747,824,600Dec 16, 2022, 04:41 PM
Gould Robert JDirectorJun 07, 2022 Option Exercise$7.8471,435560,050578,065Jun 08, 2022, 07:33 PM
Gould Robert JDirectorJun 07, 2022 Sale$8.0971,435577,895506,630Jun 08, 2022, 07:33 PM
Gould Robert JDirectorJun 06, 2022 Option Exercise$7.8424,382191,155531,012Jun 06, 2022, 07:00 PM
Gould Robert JDirectorJun 03, 2022 Option Exercise$7.8425,551200,320532,181Jun 06, 2022, 07:00 PM
Gould Robert JDirectorJun 02, 2022 Option Exercise$7.8416,689130,842523,319Jun 06, 2022, 07:00 PM
Gould Robert JDirectorJun 06, 2022 Sale$8.1024,382197,592506,630Jun 06, 2022, 07:00 PM
Gould Robert JDirectorJun 03, 2022 Sale$7.9525,551203,056506,630Jun 06, 2022, 07:00 PM
Gould Robert JDirectorJun 02, 2022 Sale$7.9216,689132,162506,630Jun 06, 2022, 07:00 PM
Gould Robert JDirectorApr 07, 2022 Option Exercise$7.845,63144,147512,261Apr 11, 2022, 05:00 PM
Gould Robert JDirectorApr 07, 2022 Sale$24.015,631135,228506,630Apr 11, 2022, 05:00 PM
Gould Robert JDirectorApr 01, 2022 Option Exercise$7.8434,464270,198541,094Apr 05, 2022, 07:00 PM
Gould Robert JDirectorApr 05, 2022 Option Exercise$7.8452,552412,008559,182Apr 05, 2022, 07:00 PM
Gould Robert JDirectorApr 04, 2022 Option Exercise$7.847,23556,722513,865Apr 05, 2022, 07:00 PM
Gould Robert JDirectorApr 05, 2022 Sale$24.2652,5521,274,775506,630Apr 05, 2022, 07:00 PM
Gould Robert JDirectorApr 04, 2022 Sale$24.027,235173,749506,630Apr 05, 2022, 07:00 PM
Gould Robert JDirectorApr 01, 2022 Sale$24.0334,464828,160506,630Apr 05, 2022, 07:00 PM
Moxham ChristopherChief Scientific OfficerAug 10, 2021 Option Exercise$7.8451,785405,99431,071Aug 12, 2021, 04:20 PM
Moxham ChristopherChief Scientific OfficerAug 10, 2021 Sale$17.6051,785911,4160Aug 12, 2021, 04:20 PM
Stuart BryanSee RemarksAug 11, 2021 Option Exercise$7.8428,000219,52028,000Aug 12, 2021, 04:20 PM
Stuart BryanSee RemarksAug 10, 2021 Option Exercise$7.8432,000250,88032,000Aug 12, 2021, 04:20 PM
Stuart BryanSee RemarksAug 11, 2021 Sale$23.7528,000665,0000Aug 12, 2021, 04:20 PM
Stuart BryanSee RemarksAug 10, 2021 Sale$17.5032,000560,0000Aug 12, 2021, 04:20 PM
Oltmans Curtis GaleSVP, General CounselJun 28, 2021 Buy$9.011,0889,8031,088Jun 29, 2021, 04:16 PM
Thomson Peter G.VP Finance & AccountingJun 28, 2021 Buy$9.002,30020,7002,300Jun 29, 2021, 04:15 PM
GERAGHTY JAMES ADirectorJun 28, 2021 Buy$9.1610,00091,60090,714Jun 29, 2021, 04:15 PM
Gould Robert JSee RemarksMar 16, 2021 Sale$12.437899,806506,630Mar 17, 2021, 04:30 PM
Gould Robert JSee RemarksMar 15, 2021 Sale$12.139,211111,773507,419Mar 17, 2021, 04:30 PM
Thomson Peter G.VP Finance & AccountingFeb 22, 2021 Option Exercise$7.845,00039,20020,212Feb 24, 2021, 04:30 PM
Thomson Peter G.VP Finance & AccountingFeb 22, 2021 Sale$14.725,00073,58215,212Feb 24, 2021, 04:30 PM
Gould Robert JSee RemarksFeb 16, 2021 Sale$14.278,215117,197518,303Feb 18, 2021, 04:30 PM
Thomson Peter G.VP Finance & AccountingJan 21, 2021 Sale$14.006,60792,49815,212Jan 25, 2021, 04:30 PM
Gould Robert JSee RemarksJan 20, 2021 Sale$12.0810,000120,826524,845Jan 22, 2021, 04:30 PM
Wallace Owen B.Chief Scientific OfficerSep 14, 2020 Option Exercise$7.846,35049,784133,438Sep 14, 2020, 04:19 PM
Wallace Owen B.Chief Scientific OfficerJul 08, 2020 Option Exercise$7.842,95123,136130,039Jul 09, 2020, 04:18 PM
Wallace Owen B.Chief Scientific OfficerJul 08, 2020 Sale$20.002,95159,020127,088Jul 09, 2020, 04:18 PM
Gould Robert JSee RemarksJul 08, 2020 Sale$20.002,50050,000534,845Jul 09, 2020, 04:15 PM
Cadavid DiegoSVP Clinical DevelopmentJul 01, 2020 Sale$18.301,07119,59965,714Jul 02, 2020, 12:00 AM
Wallace Owen B.Chief Scientific OfficerJun 30, 2020 Option Exercise$7.841411,105127,229Jul 01, 2020, 04:39 PM
Wallace Owen B.Chief Scientific OfficerJun 30, 2020 Sale$20.001412,820127,088Jul 01, 2020, 04:39 PM
Cadavid DiegoSVP Clinical DevelopmentJun 25, 2020 Option Exercise$4.831,4597,04768,244Jun 26, 2020, 04:17 PM
Cadavid DiegoSVP Clinical DevelopmentJun 25, 2020 Sale$22.001,45932,09866,785Jun 26, 2020, 04:17 PM
Gould Robert JSee RemarksJun 25, 2020 Sale$20.802,50051,992537,345Jun 26, 2020, 04:15 PM
Cadavid DiegoSVP Clinical DevelopmentJun 10, 2020 Option Exercise$4.834011,93767,186Jun 12, 2020, 05:10 PM
Cadavid DiegoSVP Clinical DevelopmentJun 10, 2020 Sale$22.004018,82266,785Jun 12, 2020, 05:10 PM
Gould Robert JSee RemarksJun 09, 2020 Sale$20.001563,120539,845Jun 10, 2020, 04:15 PM
Gould Robert JSee RemarksJun 05, 2020 Sale$20.173,43369,251540,001Jun 09, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentJun 05, 2020 Option Exercise$4.834512,17867,236Jun 08, 2020, 04:17 PM
Cadavid DiegoSVP Clinical DevelopmentJun 04, 2020 Option Exercise$4.832261,09267,011Jun 08, 2020, 04:17 PM
Cadavid DiegoSVP Clinical DevelopmentJun 05, 2020 Sale$20.184519,10166,785Jun 08, 2020, 04:17 PM
Cadavid DiegoSVP Clinical DevelopmentJun 04, 2020 Sale$20.052264,53166,785Jun 08, 2020, 04:17 PM
Gould Robert JSee RemarksJun 04, 2020 Sale$20.041,30026,058543,434Jun 05, 2020, 04:26 PM
Gould Robert JSee RemarksJun 03, 2020 Sale$20.131,50030,192544,734Jun 05, 2020, 04:26 PM
Cadavid DiegoSVP Clinical DevelopmentJun 03, 2020 Option Exercise$4.833381,63367,123Jun 04, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentJun 02, 2020 Option Exercise$4.834521766,830Jun 04, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentJun 03, 2020 Sale$20.183386,82066,785Jun 04, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentJun 02, 2020 Sale$20.004590066,785Jun 04, 2020, 04:16 PM
Gould Robert JSee RemarksJun 02, 2020 Sale$20.002,79755,940546,234Jun 03, 2020, 04:17 PM
Gould Robert JSee RemarksJun 01, 2020 Sale$20.005100549,031Jun 03, 2020, 04:17 PM
Cadavid DiegoSVP Clinical DevelopmentMay 29, 2020 Option Exercise$4.8320096666,985Jun 01, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentMay 28, 2020 Option Exercise$4.836002,89867,385Jun 01, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentMay 28, 2020 Sale$20.0060012,00066,785Jun 01, 2020, 04:16 PM
Cadavid DiegoSVP Clinical DevelopmentMay 29, 2020 Sale$20.032004,00766,785Jun 01, 2020, 04:16 PM
Gould Robert JSee RemarksMay 28, 2020 Sale$20.011,91938,391550,426Jun 01, 2020, 04:15 PM
Gould Robert JSee RemarksMay 29, 2020 Sale$20.081,39027,911549,036Jun 01, 2020, 04:15 PM
Wallace Owen B.Chief Scientific OfficerMay 28, 2020 Option Exercise$7.842,23217,499129,320Jun 01, 2020, 04:15 PM
Wallace Owen B.Chief Scientific OfficerMay 28, 2020 Sale$20.002,23244,640127,088Jun 01, 2020, 04:15 PM
Wallace Owen B.Chief Scientific OfficerMay 27, 2020 Option Exercise$7.844483,512127,536May 29, 2020, 04:15 PM
Wallace Owen B.Chief Scientific OfficerMay 27, 2020 Sale$20.004488,960127,088May 29, 2020, 04:15 PM
Wallace Owen B.Chief Scientific OfficerMay 26, 2020 Option Exercise$7.844123,230127,500May 28, 2020, 04:16 PM
Wallace Owen B.Chief Scientific OfficerMay 26, 2020 Sale$20.004128,240127,088May 28, 2020, 04:16 PM
Gould Robert JSee RemarksMay 26, 2020 Sale$20.002,50050,000552,345May 28, 2020, 04:15 PM
Cadavid DiegoSVP Clinical DevelopmentMay 12, 2020 Option Exercise$4.831,8608,98468,645May 12, 2020, 04:15 PM
Cadavid DiegoSVP Clinical DevelopmentMay 12, 2020 Sale$18.001,86033,48066,785May 12, 2020, 04:15 PM
Thomson Peter G.VP Finance & AccountingMay 11, 2020 Sale$16.007,500120,00021,071May 12, 2020, 04:15 PM
Cadavid DiegoSVP Clinical DevelopmentMar 02, 2020 Sale$17.382,14337,25567,100Mar 02, 2020, 06:42 PM
Thomson Peter G.VP Finance & AccountingFeb 24, 2020 Sale$16.835,00084,15330,923Feb 26, 2020, 07:52 PM
Gould Robert JSee RemarksFeb 19, 2020 Sale$20.002,50050,000554,845Feb 20, 2020, 04:24 PM
Wallace Owen B.Chief Scientific OfficerFeb 19, 2020 Option Exercise$7.846,08847,730133,176Feb 20, 2020, 04:23 PM
Wallace Owen B.Chief Scientific OfficerFeb 19, 2020 Sale$20.006,088121,760127,088Feb 20, 2020, 04:23 PM
Cadavid DiegoSVP Clinical DevelopmentFeb 03, 2020 Sale$17.332,14337,14268,928Feb 05, 2020, 04:31 PM
Thomson Peter G.VP Finance & AccountingJan 23, 2020 Sale$17.225,00086,10233,833Jan 27, 2020, 04:28 PM
Sanofi10% OwnerJul 22, 2019 Buy$16.0093,7501,500,000558,035Jul 23, 2019, 11:39 AM
Third Rock Ventures IV, L.P.10% OwnerJul 22, 2019 Buy$16.0081,2501,300,0002,343,154Jul 22, 2019, 04:38 PM
Third Rock Ventures III, L.P.10% OwnerJul 22, 2019 Buy$16.0081,2501,300,0005,962,202Jul 22, 2019, 04:34 PM
6 Dimensions Capital, L.P.10% OwnerJul 22, 2019 Buy$16.00118,7501,900,000559,821Jul 22, 2019, 04:32 PM
Casdin Capital, LLC10% OwnerJul 22, 2019 Buy$15.84140,0002,217,495604,285Jul 22, 2019, 04:31 PM
LEVIN MARK JDirectorJul 22, 2019 Buy$16.0081,2501,300,0005,962,202Jul 22, 2019, 04:31 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Tourangeau GregVice President, Finance03/08/202457,219
Tourangeau GregPrincipal Accounting Officer05/10/2023695
RA CAPITAL MANAGEMENT, L.P.10% Owner01/20/202324,999,988
Gould Robert JInterim President & CEO01/13/2023101,490
RA CAPITAL MANAGEMENT, L.P.10% Owner01/04/20231,314,806
RA CAPITAL MANAGEMENT, L.P.10% Owner12/27/202224,510
RA CAPITAL MANAGEMENT, L.P.10% Owner12/19/2022582,814
RA CAPITAL MANAGEMENT, L.P.10% Owner12/16/20227,269,826
RA CAPITAL MANAGEMENT, L.P.10% Owner12/15/20221,302,474
RA CAPITAL MANAGEMENT, L.P.10% Owner12/14/20224,501,574
Gould Robert JDirector06/07/2022560,050
Gould Robert JDirector06/07/2022577,895
Gould Robert JDirector06/06/2022191,155
Gould Robert JDirector06/03/2022200,320
Gould Robert JDirector06/02/2022130,842
Gould Robert JDirector06/06/2022197,592
Gould Robert JDirector06/03/2022203,056
Gould Robert JDirector06/02/2022132,162
Gould Robert JDirector04/07/202244,147
Gould Robert JDirector04/07/2022135,228
Gould Robert JDirector04/01/2022270,198
Gould Robert JDirector04/05/2022412,008
Gould Robert JDirector04/04/202256,722
Gould Robert JDirector04/05/20221,274,775
Gould Robert JDirector04/04/2022173,749
Gould Robert JDirector04/01/2022828,160
Moxham ChristopherChief Scientific Officer08/10/2021405,994
Moxham ChristopherChief Scientific Officer08/10/2021911,416
Stuart BryanSee Remarks08/11/2021219,520
Stuart BryanSee Remarks08/10/2021250,880
Stuart BryanSee Remarks08/11/2021665,000
Stuart BryanSee Remarks08/10/2021560,000
Oltmans Curtis GaleSVP, General Counsel06/28/20219,803
Thomson Peter G.VP Finance & Accounting06/28/202120,700
GERAGHTY JAMES ADirector06/28/202191,600
Gould Robert JSee Remarks03/16/20219,806
Gould Robert JSee Remarks03/15/2021111,773
Thomson Peter G.VP Finance & Accounting02/22/202139,200
Thomson Peter G.VP Finance & Accounting02/22/202173,582
Gould Robert JSee Remarks02/16/2021117,197
Thomson Peter G.VP Finance & Accounting01/21/202192,498
Gould Robert JSee Remarks01/20/2021120,826
Wallace Owen B.Chief Scientific Officer09/14/202049,784
Wallace Owen B.Chief Scientific Officer07/08/202023,136
Wallace Owen B.Chief Scientific Officer07/08/202059,020
Gould Robert JSee Remarks07/08/202050,000
Cadavid DiegoSVP Clinical Development07/01/202019,599
Wallace Owen B.Chief Scientific Officer06/30/20201,105
Wallace Owen B.Chief Scientific Officer06/30/20202,820
Cadavid DiegoSVP Clinical Development06/25/20207,047
Cadavid DiegoSVP Clinical Development06/25/202032,098
Gould Robert JSee Remarks06/25/202051,992
Cadavid DiegoSVP Clinical Development06/10/20201,937
Cadavid DiegoSVP Clinical Development06/10/20208,822
Gould Robert JSee Remarks06/09/20203,120
Gould Robert JSee Remarks06/05/202069,251
Cadavid DiegoSVP Clinical Development06/05/20202,178
Cadavid DiegoSVP Clinical Development06/04/20201,092
Cadavid DiegoSVP Clinical Development06/05/20209,101
Cadavid DiegoSVP Clinical Development06/04/20204,531
Gould Robert JSee Remarks06/04/202026,058
Gould Robert JSee Remarks06/03/202030,192
Cadavid DiegoSVP Clinical Development06/03/20201,633
Cadavid DiegoSVP Clinical Development06/02/2020217
Cadavid DiegoSVP Clinical Development06/03/20206,820
Cadavid DiegoSVP Clinical Development06/02/2020900
Gould Robert JSee Remarks06/02/202055,940
Gould Robert JSee Remarks06/01/2020100
Cadavid DiegoSVP Clinical Development05/29/2020966
Cadavid DiegoSVP Clinical Development05/28/20202,898
Cadavid DiegoSVP Clinical Development05/28/202012,000
Cadavid DiegoSVP Clinical Development05/29/20204,007
Gould Robert JSee Remarks05/28/202038,391
Gould Robert JSee Remarks05/29/202027,911
Wallace Owen B.Chief Scientific Officer05/28/202017,499
Wallace Owen B.Chief Scientific Officer05/28/202044,640
Wallace Owen B.Chief Scientific Officer05/27/20203,512
Wallace Owen B.Chief Scientific Officer05/27/20208,960
Wallace Owen B.Chief Scientific Officer05/26/20203,230
Wallace Owen B.Chief Scientific Officer05/26/20208,240
Gould Robert JSee Remarks05/26/202050,000
Cadavid DiegoSVP Clinical Development05/12/20208,984
Cadavid DiegoSVP Clinical Development05/12/202033,480
Thomson Peter G.VP Finance & Accounting05/11/2020120,000
Cadavid DiegoSVP Clinical Development03/02/202037,255
Thomson Peter G.VP Finance & Accounting02/24/202084,153
Gould Robert JSee Remarks02/19/202050,000
Wallace Owen B.Chief Scientific Officer02/19/202047,730
Wallace Owen B.Chief Scientific Officer02/19/2020121,760
Cadavid DiegoSVP Clinical Development02/03/202037,142
Thomson Peter G.VP Finance & Accounting01/23/202086,102
Sanofi10% Owner07/22/20191,500,000
Third Rock Ventures IV, L.P.10% Owner07/22/20191,300,000
Third Rock Ventures III, L.P.10% Owner07/22/20191,300,000
6 Dimensions Capital, L.P.10% Owner07/22/20191,900,000
Casdin Capital, LLC10% Owner07/22/20192,217,495
LEVIN MARK JDirector07/22/20191,300,000
Load More Insider Transactions
FUNDS WITH A POSITION IN FULCRUM THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.11,609,7041.22%No changeOther
SUVRETTA CAPITAL MANAGEMENT, LLC5,518,8811.68%-3.5%Growth At A Reasonable Price
BLACKROCK INC.1,561,8660.00027%8.02%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.1,506,4220.02%-37.4%Other
GEODE CAPITAL MANAGEMENT, LLC553,2300.00039%3.5%Other
D. E. SHAW & CO., INC.497,6790.00294%124.93%Other
BALYASNY ASSET MANAGEMENT L.P.105,1790.00133%NewEvent Driven
ALPS ADVISORS INC39,8540.00212%NewOther
BLACKSTONE INC.19,2160.00058%No changeOther
CHANGE IN SHARES OUTSTANDING FOR FULCRUM THERAPEUTICS INC
STOCK BUYBACKS FOR FULCRUM THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0.09%
1Q
12/31/2023
06/30/2023
0.13%
2Q
12/31/2023
03/31/2023
3.61%
3Q
12/31/2023
12/31/2022
18.64%
4Q
12/31/2023
09/30/2022
33.90%
5Q
12/31/2023
06/30/2022
51.33%
6Q
12/31/2023
03/31/2022
52.24%
7Q
12/31/2023
12/31/2021
52.28%
8Q
12/31/2023
09/30/2021
69.04%
9Q
12/31/2023
06/30/2021
89.60%
10Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0.09%
1Q
06/30/2023
0.13%
2Q
03/31/2023
3.61%
3Q
12/31/2022
18.64%
4Q
09/30/2022
33.90%
5Q
06/30/2022
51.33%
6Q
03/31/2022
52.24%
7Q
12/31/2021
52.28%
8Q
09/30/2021
69.04%
9Q
06/30/2021
89.60%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR FULCRUM THERAPEUTICS INC
LOADING...